A study from the University of Bern indicates that appetite-suppressing injections, originally for diabetes, improve mental health alongside curbing appetite. The findings suggest that glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, enhance mood and wellbeing, even more so than traditional antidiabetic medications. This is significant as many working-age individuals in England and Wales struggle with long-term mental health issues. The study reports positive effects in patients taking psychiatric medications, indicating these treatments could mitigate mental illness without adverse effects on mental health.
GLP-1 RAs [receptor agonists] may have antidepressant and anti-anxiety effects, potentially due to their anti-inflammatory and anti-oxidative properties, which can also help reduce neuroinflammation.
The research indicates that appetite-suppressing injections improve mood and quality of life more than insulin and other antidiabetic drugs, signifying their broader health benefits.
Collection
[
|
...
]